WHO ICTRP trial
Edaravone in COVID-19
IRCT20200317046797N6 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200317046797N6 |
|---|---|
| Public title | Edaravone in COVID-19 |
| Scientific title | Effect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19 |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Patients with COVID-2019. Coronavirus infection, unspecified;B34.2 |
| Interventions | Intervention 1: Intervention group: 15 patients with COVID-19 in addition to a standard regimen will receive 30 mg intravenous infusion edaravone (C10H10N2O, Zist Daroo Co., Iran) every 12 hours for 1 day from the beginning of… |
| Registration date | Jun 18, 2020 |
| Target size | 30 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: